STAT
NOVEMBER 4, 2023
Today STAT turns 8. In these annual letters, I usually talk proudly about all we have accomplished, from our singular coverage of the Covid pandemic to our years-in-the-making court victory to force Purdue Pharma to release documents about its OxyContin marketing efforts, to our success at becoming the go-to media outlet covering health and medicine.
Board Vitals - Pharmacist
NOVEMBER 4, 2023
Ah, the holidays – the season of giving. It’s the time of year when patients want to express their gratitude for your care with gifts that may range from the ridiculous to the sublime. They are all given with good intentions, but should you accept them? And if you do, are all gifts created equal? Is a tin of cookies the same as a gift certificate or a day of golf?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Welltopia Pharmacy
NOVEMBER 4, 2023
How to Increase Your Calcium Intake Naturally? Practical Tips for Boosting Your Dietary Calcium 1. Introduction: Calcium, the superhero The post How to Increase Your Calcium Intake Naturally? Practical Tips for Boosting Your Dietary Calcium first appeared on Welltopia Compounding Pharmacy.
EMCrit Project
NOVEMBER 4, 2023
AHA Guidelines on Critical Care Toxicology EMCrit Project by Scott Weingart, MD FCCM.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
RX Note
NOVEMBER 4, 2023
Introduction Human milk is the preferred source of nutrition for almost all neonates and infants, including those born prematurely. Major infant formula companies continuously change their products to more closely mimic the composition of human milk and to improve nutrient delivery to infants with a variety of medical conditions. Formula choice depends on many factors including age, GI function, previous tolerance or intolerance to ingredients, nutritional requirements and various disease or con
Pharmaceutical Technology
NOVEMBER 4, 2023
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharmacy Times
NOVEMBER 4, 2023
Leung discusses that various cancer types and drugs can cause thrombotic microangiopathy and impact kidney health and the renal complications connected to hematologic malignancies.
RX Note
NOVEMBER 4, 2023
Introduction Subclinical vitamin D deficiency occurs even in developed countries and is associated with osteoporosis and possibly fractures. Vitamin D stores decline with age, especially in the winter. Vitamin D Sufficiency Vitamin D sufficiency is estimated by measuring 25-hydroxyvitamin D (25[OH]D or calcidiol) concentrations. There are 4 main categories for the vitamin D status in individuals. ≥20 ng/ml (50 nmol/L): Vitamin D sufficiency 12 to 100 ng/ml (>250 nmol/ml): A "risk" of vitamin
Pharmacy Times
NOVEMBER 4, 2023
Understanding the mechanisms leading to weight loss could help identify potential benefits for cardiorenal health in patients with chronic kidney disease.
RX Note
NOVEMBER 4, 2023
Introduction Homeopathy is an alternative medical system created by German physician Samuel Hahnemann in 1796. It is based on 2 unconventional theories: "Like cures like" - the notion that a disease can be cured by a substance that produces similar symptoms in healthy people. "Law of minimum dose" - the notion that lower the dose of the medication, the greater its effectiveness.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
NOVEMBER 4, 2023
Awdishu describes the implementation of new equations to accurately drug dose in patients as well as provide updated guidance on the dosing of older medications.
Pharmaceutical Technology
NOVEMBER 4, 2023
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.
Pharmacy Times
NOVEMBER 4, 2023
Exercise has the potential to improve physical performance and fitness at the very least, but a multidisciplinary intervention may work better for patients with chronic kidney disease.
RX Note
NOVEMBER 4, 2023
Introduction Chickenpox is a highly contagious illness caused by primary infection with the varicella zoster virus, characterized by vesicular rash and fever. It is contagious from a few days before the onset of rash until all lesions have crusted over. Main route of transmission is through contact with infected persons via Inhalation of respiratory droplets and aerosols generated by skin lesions.
Pharmacy Times
NOVEMBER 4, 2023
Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.
RX Note
NOVEMBER 4, 2023
Introduction A placebo is a substance or treatment designed to have no therapeutic value. In drug testing and medical research, placebos are made to resemble active medications or therapies so that they can be used as controls. The placebo effect is a fascinating and least understood phenomenon in which a sham medical intervention (e.g. sugar pills or saline injections) causes improvements in a patient's condition due to the patient's perception of the intervention.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
Drug Patent Watch
NOVEMBER 4, 2023
This chart shows the drugs with the most patents in Morocco. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Morocco? appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
RX Note
NOVEMBER 4, 2023
Introduction Herpes zoster (also called shingles) is a localised, blistering and painful rash caused by reactivation of varicella zoster virus. After primary infection of chickenpox , varicella remains dormant in dorsal root ganglia nerve cells for years before it is reactivated and migrates down sensory nerves to the skin to cause herpes zoster. Triggering factors are sometimes recognised, such as Pressure on the nerve roots Radiotherapy at the level of the affected nerve root Spinal surgery An
Pharmaceutical Technology
NOVEMBER 4, 2023
Debio-4127 is under clinical development by Debiopharm International and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
Pharmaceutical Technology
NOVEMBER 4, 2023
Debio-4127 is under clinical development by Debiopharm International and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
Pharmaceutical Technology
NOVEMBER 4, 2023
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.
Pharmaceutical Technology
NOVEMBER 4, 2023
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.
Pharmaceutical Technology
NOVEMBER 4, 2023
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.
Pharmaceutical Technology
NOVEMBER 4, 2023
Melpida is under clinical development by Elpida Therapeutics and currently in Phase II for Paraplegia.
Pharmaceutical Technology
NOVEMBER 4, 2023
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Hypercholesterolemia.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Hypercholesterolemia.
Expert insights. Personalized for you.
315 
Let's personalize your content